Scientific Director, Professor
Department of Physiology and Pharmacology at Karolinska Institutet, Stockholm. Novo Nordisk Foundation Center for Basic Metabolic Research
Juleen Zierath's research focuses on cellular mechanisms underlying the development of insulin resistance in Type 2 Diabetes (T2DM). The overarching goal of her group is to identify and validate molecular targets that prevent or treat skeletal muscle insulin resistance in T2DM.
Her group is taking a translational approach to resolve the mechanism for peripheral insulin resistance using cell-based systems, genetically modified animal models, and clinical material from T2DM patients. In particular, Juleen Zierath's group is investigating if synchronizing exercise and nutrient interventions to the molecular circadian clock can maximize the health promoting benefit of these interventions, to enhance insulin sensitivity and prevent T2DM.
Juleen Zierath's has experimentally de-convoluted the complex interaction between distinct insulin signaling pathways that modulate divergent downstream metabolic and gene regulatory responses in skeletal muscle. She has published more than 210 research papers and 70 review articles, with key discoveries published in Science, Cell, Nature Genetics, and Cell Metabolism.